I-CLEAR Immunothrombolysis: deCoding neutrophiL Engagement in Active thrombus Resolution
- Coordinator
- Ludwig-Maximilians-Universitaet Muenchen, Germany
- Runs
- 1 January 2027 to 31 December 2031
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101303396
What the project is doing
In the project's own words, from its summary on CORDIS.
Thrombosis remains a leading global cause of morbidity and mortality. In this process inflammation has been recognised as central driver besides platelets and coagulation. My work and that of others has defined thromboinflammation, the paradigm in which neutrophil–coagulation crosstalk drives vascular occlusions in the microvasculature and macrovasculature. Recently, I introduced a previously unrecognized and paradigm-shifting concept: Neutrophils do not cease to act once a thrombus is formed.
Instead, they continuously infiltrate established clots and acquire thrombolytic properties, directly promoting thrombus-resolution. I have termed this novel process immunothrombolysis, representing the conceptual opposite to thromboinflammation. A neutrophil-driven program of endogenous thrombus-clearance challenges one of the most entrenched assumptions in vascular biology. This has profound implications: If the underlying cellular, molecular and temporal mechanisms of immunothrombolysis can be harnessed, the immune-balance could artificially be tipped early towards endogenous thrombus resolution.
I hypothesize that neutrophil–coagulation interplay exerts stage-dependent, temporo-dynamically opposing effects, culminating in immunothrombolysis. To establish this new principle, I will:1) Map the spatio-temporo-dynamic trajectories of continuous neutrophil infiltration, identifying the time and site where the switch from thromboinflammation to immunothrombolysis2) Define the molecular triggers that reprogram neutrophils into a thrombolytic phenotype driving immunothrombolysis in the macrovasculature3) Identify the molecular switches that induce endogenous microvascular thrombo-resolution to allow microvascular recanalyzation This project could redefine thrombosis biology and pioneer endogenous immune-modulation for thrombus resolution, thereby reducing systemic therapeutic bleeding risks.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Coordinator |
| Klinikum Der Ludwig-Maximilians-Universitat Munchen | Munchen | Germany | Third party |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI